LNTHNasdaqIn Vitro & In Vivo Diagnostic SubstancesUS GAAP · USD

Lantheus Holdings, Inc.

Lantheus Holdings, Inc. develops and commercializes diagnostic imaging agents used in nuclear medicine, with a portfolio centered on PET radiodiagnostics, ultrasound contrast agents, and selected legacy SPECT products. The company’s business is built around products that help clinicians detect and characterize disease, especially in oncology, cardiology, and neurology, and it also earns royalties and milestone payments from licensed products.

Kysy yhtiöstä
Liikevaihto1 542milj. USD
+0,5 %v/v
Liikevoitto (EBIT)311milj. USD
−32,0 %v/v
EBIT-marginaali20,2%
−9,6 %-yks.v/v
Nettotulos234milj. USD
−25,2 %v/v
Vapaa kassavirta390milj. USD
−28,4 %v/v

Tilikausi 2025 · muutos edellisvuodesta

Kehitys 2020–2025

−50005001 0001 5002 000milj. USD2020: 339 milj. USD2020: EBIT −4,2 milj. USD20202021: 425 milj. USD2021: EBIT −61 milj. USD20212022: 935 milj. USD2022: EBIT 36 milj. USD20222023: 1 296 milj. USD2023: EBIT 365 milj. USD20232024: 1 534 milj. USD2024: EBIT 457 milj. USD20242025: 1 542 milj. USD2025: EBIT 311 milj. USD20251 542311
LiikevaihtoLiikevoitto (EBIT)
Kysy Clarifolta: Lantheus Holdings, Inc.

Liiketoiminta

Osuus liikevaihdosta
PET radiodiagnostics60 %

PET imaging agents used to detect and stage disease, including prostate cancer and amyloid imaging.

Ultrasound contrast agents20 %

Microbubble-based agents used to improve echocardiography image quality and cardiac assessment.

SPECT diagnostics10 %

Legacy single-photon imaging products used in nuclear medicine procedures and hospital workflows.

Licensed products and royalties5 %

Economics from licensed assets such as Flyrcado, including milestone and royalty payments.

Contract manufacturing and services5 %

Manufacturing services and related radiopharmaceutical production capabilities for third parties.

Tuotteet

Raportoitu · osuus liikevaihdosta
64,2%21,4%FY2025100 %
  • PYLARIFY64,2 %
  • Definity21,4 %
  • Techne Lite5,6 %
  • Strategic Partnerships and Other3,9 %
  • Neuraceq3,3 %
  • Other Precision Diagnostics1,6 %

Lähde: 10-K FY2025, yhtiön tuotelinjoittain raportoima liikevaihto (SEC XBRL). Osuudet on laskettu näytetyistä riveistä ja ne summautuvat 100 %:iin.

Asiakkaat

Lantheus sells primarily to hospitals, imaging centers, nuclear medicine departments, and physician practices that perform diagnostic scans. Its products are bought by clinicians and healthcare systems because they improve visualization, support diagnosis, and help guide treatment decisions in oncology, cardiology, and neurology.

Hospitals and integrated health systems

Buy imaging agents for routine and specialized diagnostic workflows across nuclear medicine and echocardiography.

Outpatient imaging centers

Purchase PET and ultrasound contrast products to support high-throughput diagnostic scans.

Cardiology practices

Use DEFINITY to improve endocardial border definition and diagnostic confidence in echocardiograms.

Oncology and urology providers

Use PYLARIFY to detect PSMA-positive prostate cancer lesions and support treatment planning.

Neurology and memory care providers

Use Neuraceq for amyloid PET imaging when evaluating patients for Alzheimer’s disease.

Strategia

Lantheus is narrowing its portfolio toward higher-growth radiopharmaceuticals and PET diagnostics after selling its SPECT business in 2026. Management is also investing in lifecycle management, clinical development, and partnerships to extend the commercial life of core assets while building the next wave of imaging products.

Reposition the portfolio toward PET radiodiagnosticsLyhyt aikaväli

The SPECT sale simplifies the business and concentrates resources on higher-growth imaging categories.

Protect PYLARIFY’s commercial franchiseLyhyt aikaväli

PYLARIFY is a major revenue driver and faces reimbursement, manufacturing, and competition risks.

Expand through partnerships and licensingKeskipitkä aikaväli

Licensing can extend reach without full internal commercialization costs.

Build the next pipeline of radiopharmaceutical assetsKeskipitkä aikaväli

New products are needed to offset exclusivity expiry and sustain growth.

Maantiede

Q1/2026

Lantheus is headquartered in Massachusetts and operates with offices in New Jersey, Canada, Germany, Switzerland, Sweden, and the United Kingdom. The company’s business is global in distribution and regulatory reach, but the disclosed reports emphasize a U.S.-centered operating base with international commercial and support locations rather than a country revenue split.

USA94 %
Other countries (US filing)6,1 %

Osuus liikevaihdosta, jonka yhtiö raportoi maantieteellisesti.

Riskit

The company depends heavily on a small number of imaging products, especially PYLARIFY, so reimbursement changes, competitive launches, or loss of exclusivity could materially affect revenue. Manufacturing reliability, supply chain continuity, and regulatory compliance are also critical because these products require specialized production and distribution infrastructure.

Järjestetty vakavuuden mukaan
MatalaKohtalainenKorkeaMatalaKohtalainenKorkeaVaikutus →Todennäköisyys →PYLARIFY commercial concentration1Competition and loss of exclusivity2Regulatory and reimbursement changes3Manufacturing and supply chain disruption4Cybersecurity and AI operational risk5
Vaikutus on riskin vakavuus ja todennäköisyys sen toteutumisen todennäköisyys lähivuosina, molemmat arvioitu yhtiön raporttien perusteella. Numerot vastaavat listaa.
  1. PYLARIFY commercial concentrationVaikutus: KorkeaTodennäköisyys: Korkea

    A substantial share of revenue depends on one product and its reimbursement/access profile.

    Kohdistuu: PYLARIFY

  2. Competition and loss of exclusivityVaikutus: KorkeaTodennäköisyys: Korkea

    Competitors already market or are developing alternative PET agents and ultrasound products.

    KohdistuuPYLARIFYDEFINITYNeuraceq
  3. Regulatory and reimbursement changesVaikutus: KorkeaTodennäköisyys: Korkea

    Coverage, coding, and payment decisions directly affect adoption and net sales.

    Kohdistuu: U.S. healthcare reimbursement

  4. Manufacturing and supply chain disruptionVaikutus: KorkeaTodennäköisyys: Kohtalainen

    Radiopharmaceutical production is time-sensitive and depends on specialized facilities and inputs.

    KohdistuuPMFsRaw materialsLogisticsRadiopharmacist capacity
  5. Cybersecurity and AI operational riskVaikutus: KeskitasoTodennäköisyys: Matala

    Digital systems support research, manufacturing, and commercialization, creating attack and error exposure.

    Kohdistuu: Enterprise IT and operational systems

Kysy Clarifolta: Lantheus Holdings, Inc.

Kirjanpito

Harkinnanvaraiset erät
Revenue recognition and rebate accruals

Net sales depend on estimates for rebates, Medicaid programs, GPO fees, and distributor commissions.

Vaikutus: Can materially change reported revenue and receivables

Acquisition accounting

Life Molecular and Evergreen acquisitions introduce fair value estimates, intangibles, and post-combination expense.

Vaikutus: Affects goodwill, amortization, and operating expenses

Seasonality

Diagnostic procedure timing can soften in summer and year-end holiday periods.

Vaikutus: Quarterly comparability and working capital swings

Asset retirement and facility assurance

The North Billerica site requires decommissioning assurance via a surety bond.

Vaikutus: Relevant to contingent obligations and facility-related estimates

Samankaltaisia listattuja yhtiöitä

Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.

Lantern Pharma Inc.

LTRN · Pharmaceutical Preparations

Pasithea Therapeutics Corp.

KTTA · Pharmaceutical Preparations

LadRx Corp

Biological Products, (No Diagnostic Substances)

Radiopharm Theranostics Ltd

RDPTF · Pharmaceutical Preparations

Actinium Pharmaceuticals, Inc.

ATNM · Pharmaceutical Preparations

Sensus Healthcare, Inc.

SRTS · Surgical & Medical Instruments & Apparatus

Päivitetty: 24.9.2026

Lantheus Holdings, Inc. (LNTH) liikevaihto, tulos ja tunnusluvut 2025 – Clarifo